Researchers from the US discovered a novel epitope in the E2 subunit of the mitochondrial pyruvate dehydrogenase complex (PDC-E2).

Which of the statements below about the risk factors for sickle cell disease (SCD) are correct? Select one of the options for each question, then submit your answers to see how well you scored and how ...

Researchers delve into the current understanding of the clinical course and treatment of AATD, offering a comprehensive overview of the disease. In an ambitious overview of the documented developments ...

Currently, no consensus exists for critical ABO antibody titers to guide decisions regarding transfusions or transplants. In fact, among nongroup “O” recipients, measuring ABO titers can support a ...

Diagnostic efforts in AAV may be complicated in patients with preexisting neurodevelopmental disorders. A patient with an established diagnosis of autism and depression was diagnosed with ...

Some early adopting hospitals advocate ETCOc testing on every neonate, along with a 24-hour transcutaneous bilirubin or total serum bilirubin screen, to identify those with hemolytic conditions that ...

We previously established regression analysis to develop confidence intervals that assess the range of conduction slowing from primary demyelination in patients with CIDP. A regression equation ...

When I was first diagnosed with immune thrombocytopenia (ITP), I was completely overwhelmed. I was lost as to what was to come, what it all meant, and what was going to happen. Like most people, I ...

Regarding safety, treatment was both safe and well-tolerated by patients with relapsing-remitting MS. A phase 2 trial evaluating Hope Biosciences’ adipose-derived autologous mesenchymal stem cell ...

Drug-resistant epilepsy continues to challenge treating clinicians in cases of multifocal or generalized onset seizures. The use of responsive neurostimulation (RNS) in the bilateral pulvinar nuclei ...

Participants 6 to less than 18 years will receive avacopan in combination with rituximab or cyclophosphamide to assess remission at 26 and 52 weeks. A new phase 3 clinical trial sponsored by Amgen is ...

The Utah program ranks highest in transfusion-free rates among preterm infants across the Neonatal Research Network sites. In Seminars in Fetal and Neonatal Medicine, researchers from Utah introduced ...